Skip to main content
SpringerLink
Log in

Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.

Introduction

The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1–34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.

Methods

Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N = 65) or quarterly intravenous IBN (N = 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.

Results

Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m2, BMD L1–L4 0.741 ± 0.100 g/cm2, and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively; P < 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r 2 = 0.04) with no correlation between the changes in BMD and TBS over 24 months.

Conclusions

In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Czerwinski E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J (2007) Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 9:337–356

    PubMed  Google Scholar 

  2. Cooper C, Reginster JY, Cortet B, Diaz-Curiel M, Lorenc RS, Kanis JA, Rizzoli R (2012) Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 28:475–491

    Article  CAS  PubMed  Google Scholar 

  3. Dhanwal DK, Dennison EM, Harvey NC, Cooper C (2011) Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop 45:15–22

    Article  PubMed Central  PubMed  Google Scholar 

  4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475

    Article  PubMed  Google Scholar 

  5. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733

    Article  CAS  PubMed  Google Scholar 

  6. NIH (2001) Consensus development panel on osteoporosis prevention, diagnosis, and therapy, March 7–29, 2000: highlights of the conference. South Med J 94:569–573

    Google Scholar 

  7. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503

    Article  Google Scholar 

  8. Tucci JR (2006) Importance of early diagnosis and treatment of osteoporosis to prevent fractures. Am J Manag Care 12:S181–S190

    PubMed  Google Scholar 

  9. Report of a WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 843:1–129

    Google Scholar 

  10. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194

    Article  PubMed  Google Scholar 

  11. Hordon LD, Raisi M, Aaron JE, Paxton SK, Beneton M, Kanis JA (2000) Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: I. Two-dimensional histology. Bone 27:271–276

    Article  CAS  PubMed  Google Scholar 

  12. Link TM, Majumdar S (2004) Current diagnostic techniques in the evaluation of bone architecture. Curr Osteoporos Rep 2:47–52

    Article  PubMed  Google Scholar 

  13. Rubin CD (2005) Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin 21:1049–1056

    Article  PubMed  Google Scholar 

  14. Dalle Carbonare L, Giannini S (2004) Bone microarchitecture as an important determinant of bone strength. J Endocrinol Invest 27:99–105

    Article  CAS  PubMed  Google Scholar 

  15. Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 14:302–312

    Article  PubMed  Google Scholar 

  16. Pothuaud L, Barthe N, Krieg MA, Mehsen N, Carceller P, Hans D (2009) Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study. J Clin Densitom 12:170–176

    Article  PubMed  Google Scholar 

  17. Pothuaud L, Carceller P, Hans D (2008) Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone 42:775–787

    Article  PubMed  Google Scholar 

  18. Silva BC, Boutroy S, Zhang C et al (2013) Trabecular bone score (TBS)—a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98:1963–1970

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Del Rio LM, Winzenrieth R, Cormier C, Di Gregorio S (2013) Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case–control study. Osteoporos Int 24:991–998

    Article  PubMed  Google Scholar 

  20. Krueger D, Fidler E, Libber J, Aubry-Rozier B, Hans D, Binkley N (2013) Spine trabecular bone score subsequent to bone mineral density improves fracture discrimination in women. J Clin Densitom. doi:10.1016/j.jocd.2013.05.001

    PubMed Central  Google Scholar 

  21. Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R (2013) Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int 24:77–85

    Article  CAS  PubMed  Google Scholar 

  22. Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, Winzenrieth R, Kagamimori S, Kagawa Y, Yoneshima H (2013) Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10years independently of bone density and prevalent vertebral deformity: the Japanese population-based osteoporosis (JPOS) cohort study. J Bone Miner Res

  23. Briot K, Paternotte S, Kolta S, Eastell R, Reid DM, Felsenberg D, Gluer CC, Roux C (2013) Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: The OPUS study. Bone 57:232–236

    Article  PubMed  Google Scholar 

  24. Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 26:2762–2769

    Article  PubMed  Google Scholar 

  25. Krieg MA, Aubry-Rozier B, Hans D, Leslie WD, Manitoba Bone Density P (2013) Effects of anti-resorptive agents on trabecular bone score (TBS) in older women. Osteoporos Int 24:1073–1078

    Article  CAS  PubMed  Google Scholar 

  26. Popp AW, Guler S, Lamy O, Senn C, Buffat H, Perrelet R, Hans D, Lippuner K (2013) Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. J Bone Miner Res 28:449–454

    Article  CAS  PubMed  Google Scholar 

  27. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  28. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039

    Article  CAS  PubMed  Google Scholar 

  29. Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173–1180

    Article  CAS  PubMed  Google Scholar 

  30. Arita S, Ikeda S, Sakai A, Okimoto N, Akahoshi S, Nagashima M, Nishida A, Ito M, Nakamura T (2004) human parathyroid hormone (1–34) increases mass and structure of the cortical shell, with resultant increase in lumbar bone strength, in ovariectomized rats. J Bone Miner Metab 22:530–540

    Article  CAS  PubMed  Google Scholar 

  31. Chen P, Jerome CP, Burr DB, Turner CH, Ma YL, Rana A, Sato M (2007) Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide. J Bone Miner Res 22:841–848

    Article  CAS  PubMed  Google Scholar 

  32. Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanauskaite D, Rowell L, Felsenberg D (2010) Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46:660–665

    Article  CAS  PubMed  Google Scholar 

  33. Hans D, Downs RW Jr, Duboeuf F, Greenspan S, Jankowski LG, Kiebzak GM, Petak SM (2006) Skeletal sites for osteoporosis diagnosis: the 2005 ISCD official positions. J Clin Densitom 9:15–21

    Article  PubMed  Google Scholar 

  34. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  35. Lee YK, Nho JH, Ha YC, Koo KH (2012) Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int 23:2329–2333

    Article  CAS  PubMed  Google Scholar 

  36. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84:3076–3081

    CAS  PubMed  Google Scholar 

  37. Rakel A, Boucher A, Ste-Marie LG (2011) Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging 6:89–99

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 15:1006–1013

    Article  CAS  PubMed  Google Scholar 

  39. Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261

    Article  CAS  PubMed  Google Scholar 

  40. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941

    Article  CAS  PubMed  Google Scholar 

  41. Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S (2011) Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18months. Calcif Tissue Int 89:130–139

    Article  CAS  PubMed  Google Scholar 

  42. Fahrleitner-Pammer A, Langdahl BL, Marin F et al (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22:2709–2719

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, Juppner H, Neer RM (2009) Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 94:2495–2501

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Trevisani VF, Riera R, Imoto AM, Saconato H, Atallah AN (2008) Teriparatide (recombinant human parathyroid hormone 1–34) in postmenopausal women with osteoporosis: systematic review. Sao Paulo Med J Rev Paul Med 126:279–284

    Google Scholar 

  45. Hadji P, Zanchetta JR, Russo L et al (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150

    Article  CAS  PubMed  Google Scholar 

  46. Jakob F, Oertel H, Langdahl B et al (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 166:87–97

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Keel C, Kraenzlin ME, Kraenzlin CA, Muller B, Meier C (2010) Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab 28:68–76

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Philippe Kress, MD, for reviewing and commenting on our manuscript.

Conflicts of interest

Didier Hans is coowner of the TBS patent and has corresponding ownership shares. Christoph Senn, Beatrice Günther, Albrecht W. Popp, Romain Perrelet, and Kurt Lippuner declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne, CH-3010, Berne, Switzerland

    C. Senn, B. Günther, A. W. Popp, R. Perrelet & K. Lippuner

  2. Center of Bone Disease, Bone and Joint Department, Lausanne University Hospital, Avenue Pierre Decker 4, 1011, Lausanne, VD, Switzerland

    D. Hans

Authors
  1. C. Senn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. W. Popp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Perrelet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Hans
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Lippuner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Lippuner.

Additional information

D. Hans codirected equally the TBS study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senn, C., Günther, B., Popp, A.W. et al. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25, 1945–1951 (2014). https://doi.org/10.1007/s00198-014-2703-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-2703-8

Keywords

Search

Navigation